Mammary Cell News Volume 10.17 | May 3 2018

TOP STORY

The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression

In the current study, investigators reported AXL expression in HER2-positive breast cancers where it correlates with poor patient survival. [Cell Rep] Full Article | Graphical Abstract

(Ranked by impact factor of the journal)

Inhibitor-Induced HER2-HER3 Heterodimerisation Promotes Proliferation through a Novel Dimer Interface

The pseudokinase HER3, heterodimerisation partner of HER2, is widely implicated in the resistance to HER2-mediated therapy. Researchers showed that lapatinib, an ATP-competitive inhibitor of HER2, is able to induce proliferation cooperatively with the HER3 ligand neuregulin. [Elife] Full Article | Press Release

EPHB6 Augments Both Development and Drug Sensitivity of Triple-Negative Breast Cancer Tumors

The authors indicated that an intrinsically catalytically inactive member of the Eph group of receptor tyrosine kinases, EPHB6, partially suppresses the epithelial-mesenchymal transition in triple-negative breast cancer cells, while also promoting expansion of tumor-initiating cells. [Oncogene] Full Article

Wild-Type p53 Upregulates an Early Onset Breast Cancer-Associated Gene GAS7 to Suppress Metastasis via GAS7–CYFIP1-Mediated Signaling Pathway

To identify the genes and molecules associated with poor prognosis of early onset breast cancer, investigators examined gene expression profiles from paired breast normal/tumor tissues, coupled with Gene Ontology and public data base analysis. [Oncogene] Full Article

VEGF-Neuropilin-2 Signaling Promotes Stem-Like Traits in Breast Cancer Cells by TAZ-Mediated Repression of the Rac GAP β2-Chimaerin

Scientists found that vascular endothelial growth factor neuropilin 2 (VEGF-NRP2) signaling contributed to the activation of TAZ in various breast cancer cells, which mediated a positive feedback loop that promoted mammosphere formation. [Sci Signal] Abstract

BRD7 Inhibits the Warburg Effect and Tumor Progression through Inactivation of HIF1α/LDHA Axis in Breast Cancer

Researchers demonstrated that bromodomain-containing protein 7 (BRD7) was expressed in low levels in breast cancer tissues and was identified as a poor prognostic factor in breast cancer. [Cell Death Dis] Full Article

Cancer/Testis Antigen‐Plac1 Promotes Invasion and Metastasis of Breast Cancer through Furin/NICD/PTEN Signaling Pathway

Investigators reported that Plac1 is an important oncogenic and prognostic factor which physically interacts with Furin to drive breast cancer invasion and metastasis. [Mol Oncol] Full Article | Abstract

miR-221 Stimulates Breast Cancer Cells and Cancer-Associated Fibroblasts (CAFs) through Selective Interference with the A20/c-Rel/CTGF Signaling

Among several dysregulated miRNAs in human cancer, the up-regulation of miR-221 has been associated with development of a variety of hematologic and solid malignancies. In this study, the authors investigated the involvement of miR-221 in breast cancer. [J Exp Clin Cancer Res] Full Article

Multivalent Exposure of Trastuzumab on Iron Oxide Nanoparticles Improves Antitumor Potential and Reduces Resistance in HER2-Positive Breast Cancer Cells

In this study, multiple half chains of trastuzumab were conjugated onto magnetic iron oxide nanoparticles to develop target-specific and biologically active nanosystems to enhance anti-HER2 therapeutic potential. [Sci Rep] Full Article

Ganetespib Targets Multiple Levels of the Receptor Tyrosine Kinase Signaling Cascade and Preferentially Inhibits ErbB2-Overexpressing Breast Cancer Cells

Researchers examined the anti-cancer effects of ganetespib on ErbB2⁺ BT474 and SKBR3 breast cancer cells, and isogenic paired cancer cell lines with lentivirus-mediated ErbB2 overexpression. [Sci Rep] Full Article

Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer

Here, the authors described a novel, chimeric orthopoxvirus that efficiently kills TNBC. [Mol Ther Oncolytics] Full Article

Inflammatory Breast Cancer Biology: The Tumor Microenvironment Is Key

The authors present the intrinsic characteristics of inflammatory breast cancer (IBC), including stemness, metastatic potential and hormone receptor positivity; the extrinsic features of the IBC tumor microenvironment, including various constituent cell types; and lastly, the communication between these intrinsic and extrinsic components. [Nat Rev Cancer] Abstract

Mechanisms of Resistance in Estrogen Receptor Positive Breast Cancer: Overcoming Resistance to Tamoxifen/Aromatase Inhibitors

This review focuses on two major pathways that have recently emerged as important opportunities for therapeutic intervention in endocrine resistant breast tumors: PI3K/AKT/mTOR cell signaling and cyclinD1/cyclin-dependent kinase 4/6 cell cycle pathways. [Curr Opin Pharmacol] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Herzuma^® (Trastuzumab), a Biosimilar for the Treatment of Breast Cancer, Now Available in Europe

The Mundipharma global network of independent associated companies announced that Herzuma, biosimilar Trastuzumab, is now available in Europe, with the product now launched in both the UK and Germany and further launches across European countries anticipated in the coming months. [Mundipharma International] Press Release

Magnetic Nanoparticles Leap from Lab Bench to Breast Cancer Clinical Trials

Sandia National Laboratories materials chemist Dale Huber has worked to make nanoparticles the exact same size for 15 years. His long-term collaborators at Imagion Biosystems will use these magnetic nanoparticles for their first breast cancer clinical trial later this year. [National Technology and Engineering Solutions of Sandia, LLC.] Press Release

PreludeDx Announces DCISionRT^™ PREDICT Registry Study

Prelude Corporation, announced the official launch of its large registry study, DCISionRT PREDICT. [Prelude Corporation] Press Release

AACI to Honor Pioneer in Breast Cancer Research, Precision Medicine

AACI’s award recognizes Dr. Perou’s research accomplishments in the field of precision medicine and his groundbreaking research in the characterization of the diversity of human tumors. The clinical value of Dr. Perou’s work leading to the discovery of the “Intrinsic Subtypes of Breast Cancer” has had a profound impact on the treatment of patients with breast cancer worldwide. [AACI] Press Release

Accused Cancer Scientist Resigns as Editor of Prestigious Journal

Inder Verma, the prominent cancer scientist and geneticist who has been accused of sexual harassment by several women, resigned yesterday as editor-in-chief of the Proceedings of the National Academy of Sciences, a prestigious academic journal. [ScienceInsider] Editorial

Nature Journals Formalize Ethical Standards for Human Embryo and Stem-Cell Research

Nature journals encourage stem-cell scientists to embrace guidelines agreed in 2016 by the International Society for Stem Cell Research as they design, execute and report their research. [Nature News] Editorial

Scientists Alarmed by Report White House May Tighten Limits on Chinese Researchers in U.S.

One of the nation’s leading scientific organizations expressed alarm about a report that the White House is considering imposing further limits on research by Chinese citizens in the United States, saying that “scientific progress depends on openness, transparency, and the free flow of ideas.” [STAT News] Editorial

Nature Announces New Editor-in-chief

Nature has named Magdalena Skipper as its new editor-in-chief. She is the first woman to hold the post. Skipper, who is currently editor-in-chief of the open-access journal Nature Communications, will become the eighth editor of Nature. [Nature News] Editorial

Big UK Science Funder Says Report Harassment or Risk Losing Funding

One of the world’s largest research-funding charities is cracking down on harassment and bullying. Scientists who have been sanctioned by their institutions could lose out on funding from the Wellcome Trust, under rules announced. [Nature News] Editorial

NEW Melbourne International Breast Congress 2018
October 11-13, 2018
Melbourne, Australia

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Breast Cancer Research (Rutgers Cancer Institute of New Jersey)

NEW Project Manager – DCIS PRECISION Project (Netherlands Cancer Institute)

Graduate Student – Breast and Colorectal Cancer (Dalhousie University)

Postdoctoral Fellows – Breast Cancer Stem Cell Research (New York University School of Medicine)

Postdoctoral Fellow or Research Scientist – Breast Cancer Research (Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellowship – Cancer Research (Mass General Hospital/Harvard Medical School)

Postdoctoral Fellow – Breast Cancer Research (Northwestern University)

Postdoctoral Researcher – Breast Cancer (Baylor College of Medicine)

Senior Research Technician – Breast Cancer (Baylor College of Medicine)

Research Technician – Breast Cancer (Baylor College of Medicine)

Postdoctoral Fellow – Cancer Research (Indiana Uniersity School of Medicine)

Postdoctoral Fellows – Molecular and Translational Cancer Biology (Thomas Jefferson University)

Tenure Track Faculty Position – Cancer Research (University of Alabama at Birmingham)

Postdoctoral Researcher – Breast Cancer (UT Southwestern Medical Center)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Staff Position – Breast Cancer Tumor Immunology (Cleveland Clinic Taussig Cancer Institute)

Research Fellow – Breast Cancer (Dana-Farber Cancer Institute)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.